Compare Nu Holdings Ltd (NU) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Nuvalent Inc — how do they compare? Nu Holdings Ltd trades at $14.4 (market cap $67.58B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nu Holdings Ltd is far larger — about 6.9× Nuvalent Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NU | NUVL | |
|---|---|---|
Market Cap | $67.58B | $9.81B |
Sector | Financials | Technology |
52-Week High | $18.76 | $123.96 |
52-Week Low | $11.60 | $72.16 |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $14.39, up 5.89% in the last session, with a bullish technical signal from moving averages and strong fundamental growth. Revenue surged from $3.0B in 2022 to $10.63B in 2025, while net income turned positive to $2.87B. Recent news highlights expansion in Brazil and Mexico, including a new banking license, supporting continued growth momentum.
Outlook remains positive with a consensus price target of $14.98, though risks include rapid credit expansion and increased provisions. The stock offers exposure to Latin America's digital banking growth but faces execution risks in new markets and competitive pressures. Analyst sentiment is bullish with 55% buy ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
